← All trials
NCT05772975
Phase 3Interventional
Includes trials conducted after preliminary evidence suggesting effectiveness of the drug has been obtained, and are intended to gather additional information to evaluate the overall benefit-risk relationship of the drug.
View on ClinicalTrials.gov ↗Timeline
- Start date
- Apr 30, 2023
- Primary completion
- Dec 31, 2023
- Completion date
- May 31, 2024
- First posted
- Mar 17, 2023
- Last posted
- Mar 17, 2023
- Enrollment
- 100
- Arms / groups
- 3 / —
- Source
- AACT · ctgov ingestion
Sponsors
- University of SarajevoLead sponsor
- University of SarajevoOverall official - principal investigator
- University of SarajevoSponsor investigator
Drugs studied
Indications studied
CDEK-curated fields only — the ClinicalTrials.gov results mirror (baseline measures, adverse events, participant flow) is a separate, currently-dormant pipeline; see MIGRATION_PLAN.md.